Prognostic role of cyclin B1 in solid tumors: a meta-analysis

Chenyang Ye; Ji Wang; Pin Wu; Xiaofen Li; Ying Chai

doi:10.18632/oncotarget.13653

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Prognostic role of cyclin B1 in solid tumors: a meta-analysis

Chenyang Ye, Ji Wang, Pin Wu, Xiaofen Li and Ying Chai _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:2224-2232. https://doi.org/10.18632/oncotarget.13653

Metrics: PDF 1930 views | HTML 2352 views | ?

Abstract

Chenyang Ye1,*, Ji Wang3,*, Pin Wu2, Xiaofen Li1, Ying Chai2

1Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences), Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China

2Department of Thoracic Surgery, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China

3Department of Surgical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310016, China

*These authors contributed equally to this work

Correspondence to:

Ying Chai, email: [email protected]

Keywords: cyclin B1, solid tumors, prognosis, overall survival, meta-analysis

Received: October 07, 2016 Accepted: November 16, 2016 Published: November 26, 2016

ABSTRACT

Cyclin B1 is a key mitotic cyclin in the G2-M phase transition of the cell cycle and is overexpressed in various malignant tumors. Numerous studies have reported contradictory evidences of the correlation between cyclin B1 expression and prognosis in human solid tumors. To address this discrepancy, we conducted a meta-analysis with 17 published studies searched from PubMed and Medline. Cyclin B1 overexpression was significantly associated with poor 3-year overall survival (OS) (OR = 2.05, 95% CI = 1.20 to 3.50, P = 0.009) and 5-year OS (OR = 2.11, 95% CI = 1.33 to 3.36, P = 0.002) of solid tumors. Subgroup analysis revealed that elevated cyclin B1 expression was associated with worse prognosis of lung cancer and esophageal cancer but better prognosis of colorectal cancer. In summary, overexpression of cyclin B1 is correlated with poor survival in most solid tumors, which suggests that the expression status of cyclin B1 is a significant prognostic parameter in solid tumors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13653

Publication Alerts

Research Papers:

Prognostic role of cyclin B1 in solid tumors: a meta-analysis

Abstract